Pashtoon M. Kasi, MD, MS, University of Iowa, Iowa City, IA, discusses the results of an investigation aiming to characterize genomic alterations that are linked to targeted therapies to facilitate a personalized approach to the treatment and management of cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).